Adverse Drug Reactions in Hospitals: A Narrative Review

被引：67

作者：

Davies, Emma C. ^{[1
,3
]}

Green, Christophe F. ^{[2
]}

Mottram, David R. ^{[3
]}

Pirmohamed, Munir ^{[1
,4
]}

机构：

[1] Royal Liverpool Univ Hosp Trust, Liverpool L7 8XP, Merseyside, England

[2] Countess Chester NHS Fdn Trust, Chester CH2 1UL, Cheshire, England

[3] Liverpool John Moores Univ, Sch Pharm & Chem, Liverpool L3 3AF, Merseyside, England

[4] Univ Liverpool, Dept Pharmacol & Therapeut, Ashton St, Liverpool L69 3GE, Merseyside, England

来源：

CURRENT DRUG SAFETY | 2007年 / 2卷 / 01期

关键词：

Adverse drug reactions; hospitals;

D O I：

10.2174/157488607779315507

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The serious nature of adverse drug reactions (ADRs) has been highlighted in a number of instances over the last forty years, the most recent of these being the occurrence of serious thrombotic events with the use of COX-2 inhibitors. ADRs are estimated to be between the 4th and 6th leading cause of death in the USA, with fatal ADRs occurring in 0.32% of patients. A recent UK study showed that 6.5% of hospital admissions were related to ADRs. ADRs can therefore be regarded as a significant public health and economic problem. There is an urgent need to develop better preventive strategies to reduce the burden of ADRs. Because ADRs can affect any bodily system, can have many different clinical presentations, and are of widely variable severity, prevention will not be easy and will have to be multifactorial in its approach. This paper reviews the epidemiology of ADRs in hospitals and evaluates the research that has been undertaken to date to prevent ADRs.

引用

页码：79 / 87

页数：9

共 113 条

[1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[2] Challenges for biomedical informatics and pharmacogenomics [J].

Altman, RB ;

Klein, TE .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2002, 42 :113-133

[3] Aging liver [J].

Anantharaju, A ;

Feller, A ;

Chedid, A .

GERONTOLOGY, 2002, 48 (06) :343-353

[4] Joining the DoTS: new approach to classifying adverse drug reactions [J].

Aronson, JK ;

Ferner, RE .

BRITISH MEDICAL JOURNAL, 2003, 327 (7425) :1222-1225

[5]

Aronson JK, 2002, DAVIDSONS PRINCIPLES, P148

[6] Computerized surveillance of adverse drug reactions in hospital: pilot study [J].

Azaz-Livshits, T ;

Levy, M ;

Sadan, B ;

Shalit, M ;

Geisslinger, G ;

Brune, K .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (03) :309-314

[7] INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION [J].

BATES, DW ;

CULLEN, DJ ;

LAIRD, N ;

PETERSEN, LA ;

SMALL, SD ;

SERVI, D ;

LAFFEL, G ;

SWEITZER, BJ ;

SHEA, BF ;

HALLISEY, R ;

VANDERVLIET, M ;

NEMESKAL, R ;

LEAPE, LL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (01) :29-34

[8] The costs of adverse drug events in hospitalized patients [J].

Bates, DW ;

Spell, N ;

Cullen, DJ ;

Burdick, E ;

Laird, N ;

Petersen, LA ;

Small, SD ;

Sweitzer, BJ ;

Leape, LL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :307-311

[9] Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies [J].

Beijer, HJM ;

de Blaey, CJ .

PHARMACY WORLD & SCIENCE, 2002, 24 (02) :46-54

[10] Analysis of the direct cost of adverse drug reactions in hospitalised patients [J].

Bordet, R ;

Gautier, S ;

Le Louet, H ;

Dupuis, B ;

Caron, J .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 56 (12) :935-941

← 1 2 3 4 5 6 7 8 9 10 →